Multiple Sclerosis Market Key multiple sclerosis companies such as Sanofi, Immunic, InnoCare Pharma, Tiziana Life Sciences, Biogen, J-Pharma, Bristol-Myers Squibb, Polpharma Biologics, Repertoire Immune Medicines, Nervgen, Nucleome Therapeutics, Medsenic, TeraImmun,
Multiple Sclerosis Market Forecast 2034: Competitive Landscape, FDA Approvals, Therapies, Emerging Drugs Highlighting Zenas Biopharma’s Obexelimab Phase 2 Success and Market Insights
DelveInsight’s “Food Allergy Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Food Allergy pipeline landscape. It covers the Food Allergy pipeline drug
DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy Pipeline Insight 2025” report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in the Chemotherapy Induced Peripheral Neuropathy pipeline landscape. It covers the
DelveInsight’s, “Myocardial Infarction Pipeline Insight 2025” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers the Myocardial Infarction pipeline drug profiles,
DelveInsight’s “Epilepsy Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in the Epilepsy pipeline
Chronic Hepatitis B market The Chronic Hepatitis B (CHB) market across the seven major markets (7MM), the United States, EU4
Multiple Sclerosis market The leading Multiple Sclerosis Companies, such as Roche, Sanofi, Novartis, and AB Science, among others, are progressing
Hyperparathyroidism market PARSABIV and RAYALDEE are approved in the US for secondary hyperparathyroidism, whereas ORKEDIA and UPASITA are approved in
Global KRAS Inhibitors Market Among the 7MM, the United States captured the highest KRAS inhibitors market size in 2024, accounting
HER2-low cancers market Recent FDA approval of ENHERTU in HER2-low/ultralow breast cancer has validated HER2-low as a key therapeutic target.
